Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Reprod Biol Endocrinol ; 13: 134, 2015 Dec 16.
Article in English | MEDLINE | ID: mdl-26669322

ABSTRACT

BACKGROUND: Lifestyle factors including cigarette smoking, alcohol consumption and nutritional habits impact on health, wellness, and the risk of chronic diseases. In the areas of in-vitro fertilization (IVF) and pregnancy, lifestyle factors influence oocyte production, fertilization rates, pregnancy and pregnancy loss, while chronic, low-grade oxidative stress may underlie poor outcomes for some IVF cases. METHODS: Here, we review the current literature and present some original, previously unpublished data, obtained from couples attending the PIVET Medical Centre in Western Australia. RESULTS: During the study, 80 % of females and 70 % of male partners completed a 1-week diary documenting their smoking, alcohol and fruit and vegetable intake. The subsequent clinical outcomes of their IVF treatment such as quantity of oocytes collected, fertilization rates, pregnancy and pregnancy loss were submitted to multiple regression analysis, in order to investigate the relationship between patients, treatment and the recorded lifestyle factors. Of significance, it was found that male smoking caused an increased risk of pregnancy loss (p = 0.029), while female smoking caused an adverse effect on ovarian reserve. Both alcohol consumption (ß = 0.074, p < 0.001) and fruit and vegetable consumption (ß = 0.034, p < 0.001) had positive effects on fertilization. CONCLUSION: Based on our results and the current literature, there is an important impact of lifestyle factors on IVF clinical outcomes. Currently, there are conflicting results regarding other lifestyle factors such as nutritional habits and alcohol consumption, but it is apparent that chronic oxidative stress induced by lifestyle factors and poor nutritional habits associate with a lower rate of IVF success.


Subject(s)
Alcohol Drinking , Diet , Fertilization in Vitro , Fruit , Smoking , Vegetables , Adult , Female , Humans , Life Style , Pregnancy , Pregnancy Outcome , Treatment Outcome
3.
J Alzheimers Dis ; 13(3): 267-74, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18430994

ABSTRACT

Recent research studies associate elevated gonadotropin levels with dementia. Specifically, an age associated increase in levels of luteinizing hormone has been linked to an increased risk of Alzheimer's disease. The objective of this study was to investigate the association between gonadotropin levels and cognition in older, healthy postmenopausal women. Cognitive functioning was compared with plasma levels of estradiol, luteinizing hormone, follicle stimulating hormone, Abeta40 and APOE genetic status in 649 community-dwelling, non-demented older women residing in Western Australia. High endogenous luteinizing hormone levels were associated with a lower cognitive score, especially in older women and in those women that were depressed. Unexpectedly, disproportionately well preserved cognitive functioning was found for the oldest women who had high endogenous levels of follicle stimulating hormone. The findings indicate that gonadotropins can impact upon cognitive functioning in older postmenopausal women, and that luteinizing hormone and follicle stimulating hormone may exert contrasting effects. Taken together, the findings have important implications for the development of possible preventive strategies for dementia.


Subject(s)
Cognition Disorders/blood , Cognition Disorders/epidemiology , Gonadotropins/blood , Aged , Aged, 80 and over , Cognition Disorders/diagnosis , Estradiol/blood , Female , Follicle Stimulating Hormone/blood , Gonadotropin-Releasing Hormone/blood , Humans , Luteinizing Hormone/blood , Neuropsychological Tests , Postmenopause , Predictive Value of Tests , Prevalence , Severity of Illness Index
4.
J Neurotrauma ; 24(1): 154-62, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17263679

ABSTRACT

Patients with traumatic brain injury (TBI) are predisposed to heterotopic ossification, which is believed to be due to osteoinductive factors released at the site of the brain injury. To date, little is known about the presence of such factors in human cerebrospinal fluid (CSF). This study investigated whether CSF of TBI patients is osteoinductive. In addition, known osteoinductive factors--such as bone morphogenetic protein (BMP)-2, BMP-4, and BMP-7, and S100B--were measured in CSF. Eighty-four consecutive patients were classified according to brain pathology: TBI (n = 11), non-traumatic brain pathology (NTBP) (n = 26), and no brain pathology (control group) (n = 47). The osteoinductive effect of CSF was measured repeatedly in proliferation assays using a fetal human osteoblast cell line. The mean proliferation rate (normalized to the internal negative control) of the TBI, NTBP, and control groups was 138.2% (SD 13.1), 110.0% (SD 22.1), and 118.8% (SD 16.9), respectively. The potentially confounding effect of age was investigated further by restricting the selection of patients for analysis to that of the oldest patient in the TBI group and use of multiple regression analysis. After implementation of both, it was shown that age is highly unlikely to account for the higher rates of proliferation observed among the TBI patients in this study. Of note, the TBI group had a significantly higher mean proliferation rate than the NTBP (p = 0.001) and the control group (p = 0.006). S100B and BMP-2, -4, or -7 concentrations were measured using enzyme-linked immunosorbent assay (ELISA). There was no correlation between proliferation rates and S100B (r = 0.023). Only three of 36 CSF samples had measurable levels of BMP-2 and -7, and none had detectable concentrations of BMP-4. Consequently, it is unlikely that S100B or BMP-2, -4, or -7 are the putative osteoinductive factors. The results indicate that CSF from TBI patients has an osteoinductive effect in vitro. However, the osteoinductive factor has still to be characterized.


Subject(s)
Brain Injuries/cerebrospinal fluid , Cerebrospinal Fluid/physiology , Ossification, Heterotopic/cerebrospinal fluid , Ossification, Heterotopic/chemically induced , Adolescent , Adult , Aged , Aged, 80 and over , Aging/physiology , Bone Morphogenetic Protein 2 , Bone Morphogenetic Protein 4 , Bone Morphogenetic Protein 7 , Bone Morphogenetic Proteins/cerebrospinal fluid , Cell Line , Cell Proliferation/drug effects , Cells, Cultured , Female , Humans , Linear Models , Male , Middle Aged , Nerve Growth Factors/physiology , S100 Calcium Binding Protein beta Subunit , S100 Proteins/physiology , Skull Fractures/cerebrospinal fluid , Transforming Growth Factor beta/cerebrospinal fluid
5.
ANZ J Surg ; 73(11): 932-7, 2003 Nov.
Article in English | MEDLINE | ID: mdl-14616574

ABSTRACT

BACKGROUND: Effective strategies for the prevention of adverse vascular events in patients with atherosclerotic vascular disease include smoking cessation, platelet inhibition, antihypertensives, hypoglycaemic and cholesterol lowering agents. The current literature suggests that these practices are suboptimal in patients with peripheral vascular disease (PVD). This study aims to examine and compare the use of preventive therapy in patients admitted for interventions related to peripheral and carotid atherosclerotic occlusive disease. METHODS: All inpatients undergoing diagnostic or therapeutic procedures for occlusive disease of the lower limb and carotid artery at Royal Perth Hospital, Western Australia, between January 2000 and December 2000 were included in the study. Their medical charts were reviewed to measure the prevalence of the use of antithrombotic, antihypertensive and cholesterol-lowering therapies. RESULTS: Medical charts of 256 patients (97%) were reviewed during the study period. Carotid related procedures accounted for 26% of the sample. Overall, 80% were prescribed antithrombotic (antiplatelet or anticoagulation) therapy at the time of discharge. In the carotid group, 97% were on some form of antithrombotic therapy as opposed to 75% in the PVD group. Antihypertensive and cholesterol lowering therapies were used in 82% and 63%, respectively, of the carotid group vs 68% and 36% in the PVD group. Rates of preventive practices were lowest in the subgroup of PVD patients without a history of coronary or cerebrovascular disease. CONCLUSIONS: Preventive therapies are under utilized in patients with PVD. Effective strategies need to be developed to encourage the use of these adjunctive therapies in the long-term management of vascular patients.


Subject(s)
Anticholesteremic Agents/administration & dosage , Antihypertensive Agents/administration & dosage , Arteriosclerosis/prevention & control , Carotid Stenosis/prevention & control , Fibrinolytic Agents/administration & dosage , Peripheral Vascular Diseases/prevention & control , Aged , Arteriosclerosis/drug therapy , Arteriosclerosis/surgery , Carotid Stenosis/drug therapy , Carotid Stenosis/surgery , Female , Humans , Male , Peripheral Vascular Diseases/drug therapy , Peripheral Vascular Diseases/surgery , Retrospective Studies
SELECTION OF CITATIONS
SEARCH DETAIL
...